We are live on
!
Find out more
GFM
GF Fund Management Portfolio holdings
AUM
$5.98B
1-Year Est. Return
80.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.56B
Cap. Flow
% of AUM
98.7%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$400M |
| 2 |
Apple
AAPL
|
+$352M |
| 3 |
Microsoft
MSFT
|
+$326M |
| 4 |
Amazon
AMZN
|
+$218M |
| 5 |
Meta Platforms (Facebook)
META
|
+$195M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.41% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Diamondrock Hospitality Co
DRH
$2.64B
| $34K | ﹤0.01% |
+3,766
| New | +$34.4K |
|
427
Structure Therapeutics
GPCR
$3.52B
| $33.9K | ﹤0.01% |
+1,251
| New | +$44.4K |
|
428
Xencor
XNCR
$1.59B
| $33.8K | ﹤0.01% |
+1,469
| New | +$33.8K |
|
429
BioCryst Pharmaceuticals
BCRX
$2.35B
| $32.7K | ﹤0.01% |
+4,349
| New | +$33K |
|
430
10x Genomics
TXG
$6.28B
| $32.3K | ﹤0.01% |
+2,247
| New | +$35.5K |
|
431
Travere Therapeutics
TVTX
$5.33B
| $31.4K | ﹤0.01% |
+1,803
| New | +$31.9K |
|
|
CNTA
432
DELISTED
Centessa Pharmaceuticals
CNTA
| $31.4K | ﹤0.01% |
+1,872
| New | +$31K |
|
433
Praxis Precision Medicines
PRAX
$8.58B
| $30.1K | ﹤0.01% |
+391
| New | +$28.3K |
|
434
Pebblebrook Hotel Trust
PEB
$2.12B
| $29.7K | ﹤0.01% |
+2,190
| New | +$28.9K |
|
435
RLJ Lodging Trust
RLJ
$1.87B
| $28.8K | ﹤0.01% |
+2,817
| New | +$27.3K |
|
436
Spyre Therapeutics
SYRE
$8.81B
| $28.7K | ﹤0.01% |
+1,232
| New | +$36.1K |
|
437
Zai Lab
ZLAB
$2.06B
| $28.7K | ﹤0.01% |
+1,095
| New | +$30.4K |
|
438
Ocular Therapeutix
OCUL
$1.85B
| $28.2K | ﹤0.01% |
+3,301
| New | +$32.2K |
|
|
GTY
439
Getty Realty Corp
GTY
$2.12B
| $28.2K | ﹤0.01% |
+935
| New | +$29.7K |
|
440
Nurix Therapeutics
NRIX
$2.45B
| $28K | ﹤0.01% |
+1,487
| New | +$34.1K |
|
441
Arvinas
ARVN
$536M
| $27.7K | ﹤0.01% |
+1,443
| New | +$35.1K |
|
|
XHR
442
Xenia Hotels & Resorts
XHR
$1.85B
| $27.5K | ﹤0.01% |
+1,853
| New | +$28K |
|
|
LTC
443
LTC Properties
LTC
$2.06B
| $27.3K | ﹤0.01% |
+790
| New | +$29.2K |
|
444
Novavax
NVAX
$1.22B
| $27K | ﹤0.01% |
+3,363
| New | +$32.4K |
|
445
Aurinia Pharmaceuticals
AUPH
$1.93B
| $27K | ﹤0.01% |
+3,006
| New | +$24.5K |
|
|
DAWN
446
DELISTED
Day One Biopharmaceuticals
DAWN
| $26.8K | ﹤0.01% |
+2,117
| New | +$29.5K |
|
447
Empire State Realty Trust
ESRT
$862M
| $26.4K | ﹤0.01% |
+2,557
| New | +$27.7K |
|
448
Global Net Lease
GNL
$1.86B
| $26K | ﹤0.01% |
+3,560
| New | +$27.3K |
|
|
UMH
449
UMH Properties
UMH
$1.3B
| $25.6K | ﹤0.01% |
+1,356
| New | +$25.9K |
|
450
Ardelyx
ARDX
$1.25B
| $25.2K | ﹤0.01% |
+4,973
| New | +$27.5K |
|
Similar funds
CM
BP
AAM
CAG
RCG
AL
CGPCS
EAM
GF Fund Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.
Its largest position is NVIDIA: 2,904,119 shares worth $390M.
By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.
- GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
- GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
- GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.
Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.